Description
Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
Amendment chain · 4 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $4,166,796 at start, $10,000,000 after amendment #4 (+$5,833,204).
- #12020-12-24$4,166,796
- #22021-06-15$6,425,932+$2,259,136
- #32022-01-04$10,000,000+$3,574,068
- #42022-11-28$10,000,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-12-24 | $4,166,796 | — | Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection. |
| #2 amendment | 2021-06-15 | $6,425,932 | +$2,259,136 | Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection. |
| #3 amendment | 2022-01-04 | $10,000,000 | +$3,574,068 | Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection. |
| #4 amendment | 2022-11-28 | $10,000,000 | +$0 | Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection. |
Related records · 10
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 835517442)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2022-2023-Q4-1002706 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $7,000,000 | FY2023 |
| 172-2020-2021-Q4-967293 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $21,676 | FY2021 |
| 172-2020-2021-Q3-960877 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $48,704 | FY2021 |
| 172-2020-2021-Q1-949490 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $40,656 | FY2021 |
| 172-2019-2020-Q3-939069 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $665,000 | FY2020 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-958708 · retrieved 2026-11-16.